Practically Speaking: Special Relativity-047 Nivo RELA in advanced melanoma.

To be added to the distribution list, please email: DDeCastro@southlake.ca

In this episode of MedOncNow, Dr. Sam Saibil discusses Nivolumab + Relatlimab in the 1st line treatment of Advanced Melanoma.  This is discussed in the context of Nivolumab + Ipilimumab as the current standard of care. This is timely given we now have access to funded Nivolumab + Relatlimab in the 1st line setting in many jurisdiction. 

Key Opinion Leader: 

Sam Saibil MD, PhD, FRCPC
Staff Oncologist, Princess Margaret Cancer Centre
Assistant Professor, University of Toronto
Hold'em For Life Professor in Cancer Research

Host:
Shaqil Kassam MD. MSc. FRCPC
skassam@southlake.ca
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

Previous episodes: https://www.blogtalkradio.com/medoncnow

X- @medoncnow